🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchInsulin icodec (Awiqli) — need advice Page 6

Insulin icodec (Awiqli) — need advice

VendorMark Mon, Feb 2, 2026 at 1:53 AM 31 replies 1,494 viewsPage 6 of 7
mike_mealprep
Member
412
1,890
Jul 2024
Chicago, IL
Feb 8, 2026 at 5:25 AM#26
LabKate said:
One habit that pays for itself: post the method alongside the number.

True, with the qualification that this is a self-selected group. The people for whom it did not work post less, and that shapes everything we think we know.

6 4mia_MS2, LeilaHI, marcus_mpls and 3 others
Reply Quote Save Share Report
JenMemphis
Member
267
1,234
Jan 2025
Memphis, TN
Feb 8, 2026 at 8:57 PM#27
LabKate said:
One habit that pays for itself: post the method alongside the number.

That reframing is the part I needed.

Last edited: Feb 9, 2026 at 1:57 AM
7 5BenResearch_OR, MikeKY_noInsulin, Dr.RaviCardio and 4 others
Reply Quote Save Share Report
jim_asheville
Member
289
1,234
Aug 2024
Asheville, NC
Feb 9, 2026 at 12:28 PM#28

Clinical perspective, offered as context rather than as advice. The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either. Those three things can all be true at once, and most arguments here are two people holding different parts of that.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

8 6NurseAsh_DET, BenResearch_OR, MikeKY_noInsulin and 5 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
B12Beth
Member
289
890
Oct 2024
Maryland
Feb 10, 2026 at 3:59 AM#29
jim_asheville said:
The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either.

This is my experience too, for whatever a second data point is worth. Nothing to add that would improve it.

9 7marco_milano, pam_columbus, nick_SD_fit and 6 others
Reply Quote Save Share Report
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
Feb 10, 2026 at 7:29 PM#30

Closing the loop on my own question.

Update — my curve sits below the published mean and the explanation is that the trial arm had support I do not have. That was reassuring rather than otherwise.

31 4claudia_zurich, nancy_portland, rick_sfbay and 28 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register